# EDGAR Filing Document

**Accession Number:** 0001728117
**File Stem:** 0001728117-25-000069
**Filing Date:** 2025-8
**Character Count:** 19229
**Document Hash:** 1b9b4b88e2ecd6963acddf3d836f1f9b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001728117-25-000069.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001728117-25-000069

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250805

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Gossamer Bio, Inc.
- **CENTRAL INDEX KEY:** 0001728117
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475461709
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38796
- **FILM NUMBER:** 251184774

**BUSINESS ADDRESS:**
- **STREET 1:** 3115 MERRYFIELD ROW
- **STREET 2:** SUITE 120
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 684-1300

**MAIL ADDRESS:**
- **STREET 1:** 3115 MERRYFIELD ROW
- **STREET 2:** SUITE 120
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

?xml version='1.0' encoding='ASCII'? goss-20250805

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

 

**FORM 8-K**

 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 5, 2025**

 

**GOSSAMER BIO, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38796** | **47-5461709** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |

---

**3115 Merryfield Row, Suite 120**

**San Diego, California, 92121**

**(Address of Principal Executive Offices) (Zip Code)**

**(858) 684-1300**

**(Registrant's Telephone Number, Including Area Code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | GOSS | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On August 5, 2025, Gossamer Bio, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release attached as Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | <u>[Press Release](goss-20250805xexx991.htm)</u> <u>dated August 5, 2025</u>  |
| 101 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | GOSSAMER BIO, INC. | GOSSAMER BIO, INC. |
| Date: August 5, 2025 | By: | /s/ Bryan Giraudo |
|  |  | Bryan Giraudo |
|  |  | Chief Financial Officer and Chief Operating Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![newgosslogo.jpg](newgosslogo.jpg)

**Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update**

*- Topline Results from PROSERA Phase 3 Expected in February 2026 -*

*- First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the Fourth Quarter of 2025 -*

*- Cash, cash equivalents and marketable securities totaled $213 million as of June 30, 2025 -*

SAN DIEGO—(BUSINESS WIRE)— August 5, 2025 — Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.

"It is an exciting time at Gossamer. We are currently well underway with commercial planning for seralutinib, in partnership with Chiesi Group, as we prepare to evolve from a clinical-stage biotech into a commercial organization. Additionally, we are preparing for the initiation of a global, registrational Phase 3 clinical study in PH-ILD, the SERANATA Study, for which we expect to activate the first clinical sites in the fourth quarter of this year," said Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio.

"And while our potential first-in-class therapeutic, seralutinib, represents the possibility of a multi-billion-dollar opportunity across multiple indications, we recognize the unique significance of the upcoming pivotal readout in PAH as the foundation to that potential franchise. Our team remains duly focused on executing the PROSERA Study with discipline and operational excellence, grounded in our conviction around the strength of the science and the seriousness of the unmet need in PAH. We look forward to sharing topline results in February."

**Seralutinib (GB002): Inhaled PDGFR, CSF1R and c-KIT Inhibitor**

**Pulmonary Arterial Hypertension (PAH)**

• &nbsp;&nbsp;&nbsp;&nbsp;On June 11th, we completed enrollment for the ongoing Phase 3 PROSERA Study with 390 Functional Class II and III PAH patients. The PROSERA Study is a double-blind, placebo-controlled, global registrational clinical trial evaluating seralutinib in PAH patients, on top of background PAH therapy. Patients are randomized 1:1 to either the seralutinib or placebo arms. Patients receive blinded treatment for up to 48 weeks.

• &nbsp;&nbsp;&nbsp;&nbsp;The primary endpoint of the PROSERA Study is change in six-minute walk distance (6MWD) from baseline as compared to placebo at week 24. Included in the key secondary endpoints is time to clinical worsening, as compared to placebo, up to week 48. In addition to other secondary and exploratory endpoints, safety and tolerability will be evaluated.

------

• &nbsp;&nbsp;&nbsp;&nbsp;We expect to announce topline results from the ongoing Phase 3 PROSERA Study in February 2026.

• &nbsp;&nbsp;&nbsp;&nbsp;On June 16th, we announced select preliminary baseline patient characteristics related to the ongoing PROSERA Study.

**Baseline Characteristics: Phase 3 PROSERA Study v. Phase 2 TORREY Study**

---

| | | |
|:---|:---|:---|
| | PROSERA Phase 3\* | TORREY Phase 2 |
| Study Participants | n = 390 | n = 86 |
| Mean 6MWD | 374 meters | 408 meters |
| Mean NT-proBNP | 987 ng/L | 628 ng/L |
| Functional Class III Patients | 290 (74%) | 36 (42%) |
| Geographic Distribution | North America: 75 (19%)<br>Rest of World: 315 (81%) | North America: 59 (69%)<br>Rest of World: 27 (31%) |
| *\*Baseline characteristics are preliminary and subject to change.* | *\*Baseline characteristics are preliminary and subject to change.* | *\*Baseline characteristics are preliminary and subject to change.* |

---

• &nbsp;&nbsp;&nbsp;&nbsp;One poster related to seralutinib was presented at the American Thoracic Society (ATS) 2025 International Conference, which took place from May 16th through 21st, in San Francisco, California.

o&nbsp;&nbsp;&nbsp;&nbsp;Seralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation \| Available Here: https://www.gossamerbio.com/wp-content/uploads/2025/05/poster-ats25a.pdf

**Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)**

• We expect to activate the first clinical sites for the global, registrational Phase 3 SERANATA Study in PH-ILD patients in the fourth quarter of 2025.

• The planned SERANATA Study will be a 24-week, randomized, double-blind, placebo-controlled, global clinical trial in PH-ILD patients. Approximately 480 patients will be randomized 1:1:1 to receive either 90mg seralutinib twice-daily, 120mg seralutinib twice-daily or placebo.

• The primary endpoint of the SERANATA Study is change in 6MWD from baseline as compared to placebo at week 24. Key secondary endpoints will include time to clinical worsening and change from baseline in forced vital capacity (FVC).

**Financial Results for Quarter Ended June 30, 2025**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash, Cash Equivalents and Marketable Securities**: Cash, cash equivalents and marketable securities as of June 30, 2025, were $212.9 million. We expect the combination of current cash, cash equivalents and marketable securities will be sufficient to fund our operating and capital expenditures into 2027.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Revenue from Sale of Licenses and from Contracts with Collaborators**: For the quarter ended June 30, 2025, revenue associated with our collaboration with Chiesi was $11.5 million, including $7.6 million of cost reimbursement revenue, compared to $95.8 million for the same period in 2024, which included $88.8 million of revenue related to a one-time sale of license related to the collaboration with Chiesi.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Research and Development (R&D) Expenses**: For the quarter ended June 30, 2025, R&D expenses were $41.6 million, compared to $35.1 million for the same period in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **General and Administrative (G&A) Expenses**: For the quarter ended June 30, 2025, G&A expenses were $8.7 million, compared to $8.7 million for the same period in 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Net Income (Loss)**: Net loss for the quarter ended June 30, 2025, was $38.3 million, or $0.17 basic net loss per share, compared to net income of $49.2 million, or $0.22 basic net income per share, for the same period in 2024. The year-over-year change in net income is primarily attributable to the $88.8 million in one-time license revenue recognized in the second quarter of 2024 related to the collaboration with Chiesi.

**About Gossamer Bio**

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

**Forward-Looking Statements**

Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the anticipated timing of a data readout from our Phase 3 PROSERA Study; the potential or likelihood for a meaningful data readout from our PROSERA Study; the development potential and market opportunity of seralutinib in PAH, PH-ILD and other indications; the ability to successfully transition to a commercial organization, the anticipated timing on commencing a Phase 3 clinical trial in PH-ILD; and the expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamer's business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; disruption to our operations from unexpected events, including clinical trial delays; the Company's dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials with seralutinib are not necessarily predictive of future results; the success of Gossamer's clinical trials and preclinical studies for seralutinib; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of seralutinib that may limit its development, regulatory approval and/or commercialization, or may result in clinical holds, recalls or product liability claims; Gossamer's ability to obtain and maintain intellectual property protection for seralutinib; Gossamer's ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect our business and financial condition and the broader economy and biotechnology industry; Gossamer may use its capital resources sooner than it expects; and other risks described in the Company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in the Company's annual report on Form 10-K and any subsequent filings with the SEC.

------

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

**Gossamer Bio Statement of Operations**

**Condensed Consolidated Statement of Operations**

**(in thousands, except share and per share amounts)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended June 30,** | **Three months ended June 30,** | **Six months ended June 30,** | **Six months ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Revenue:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue from sale of licenses | $— | $88751 | $— | $88751 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue from contracts with collaborators | 11489 | 7091 | 21378 | 7091 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total revenue** | 11489 | 95842 | 21378 | 95842 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | 41575 | 35086 | 79616 | 67478 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 8679 | 8669 | 17337 | 18236 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 50254 | 43755 | 96953 | 85714 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Income (loss) from operations** | **(38765)** | **52087** | **(75575)** | **10128** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 542 | 1749 | 836 | 2093 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (2744) | (2916) | (5490) | (6045) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 2694 | 2747 | 5318 | 5563 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other income, net | 492 | 1580 | 664 | 1611 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Income (loss) before provision for income taxes** | **(38273)** | **53667** | **(74911)** | **11739** |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes |  | 4435 |  | 4435 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $**(38273)** | $**49232** | $**(74911)** | $**7304** |
| Net income (loss) per share, basic | $(0.17) | $0.22 | $(0.33) | $0.03 |
| Net income (loss) per share, diluted | $(0.17) | $0.22 | $(0.33) | $0.03 |
| Weighted average common shares outstanding, basic | 227275466 | 226221202 | 227048022 | 225978219 |
| Weighted average common shares outstanding, diluted | 227275466 | 238543102 | 227048022 | 225978219 |

---

------

**Condensed Consolidated Balance Sheet**

**(in thousands)**

---

| | | |
|:---|:---|:---|
| **BALANCE SHEET DATA:** | **June 30, 2025** | **December 31, 2024** |
|  | (unaudited) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents, and marketable securities | $212918 | $294518 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Working capital | 182304 | 264878 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | 240925 | 315292 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 287032 | 285800 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (1343479) | (1268568) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity (deficit) | (46107) | 29492 |

---

------

**For Investors and Media:** 

Bryan Giraudo, Chief Financial Officer & Chief Operating Officer

Gossamer Bio Investor Relations

ir@gossamerbio.com

<br>